Antisoma’s candidate will be evaluated in renal cancer and AML.

Microtest signed a deal with Antisoma to immediately begin the aseptic manufacturing of AS1411, a drug being developed for the treatment of various cancers.

“AS1411 is the first aptamer to be tested in cancer clinical trials. After successfully completing Phase I trials, we are now advancing to Phase II trials in renal cancer and AML,” says Glyn Edwards, Antisoma’s CEO.

Microtest will be responsible for the formulation and aseptic fill/finish of AS1411 material supply for forthcoming Phase II trials. In addition, it will be responsible for stability testing of the AS1411 product.

Previous articleBradley to Make a $7M Milestone Payment to BioSante and Antares
Next articleUniversity of British Columbia Researchers Discover Immune-Boosting Peptide